1. Pink Sheet
  2. >>Legal & IP
  3. >>Patents

US Patent Office Plan To Expand Settlement Disclosure Requirements Welcomed By FTC

 
• By Cathy Kelly

US Federal Trade Commission says the policy would enhance its ability to detect reverse payment settlements between pharmaceutical companies that raise antitrust concerns.

Efforts are Ongoing To Improve PTAB Processes. • Source: Shutterstock

The US Federal Trade Commission praised a proposal to close a patent settlement disclosure loophole from the Patent and Trademark Office, arguing it will ensure more of the agreements are reported.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Patents

Supreme Court May Be Next After Federal Circuit Refuses To Rehear Teva Inhaler Patents Case

 
• By Urtė Fultinavičiūtė

Teva was forced to delist its ProAir HFA inhaler patents from the FDA’s Orange Book by mid-March after the Federal Circuit denied its petition for en banc rehearing. Will the Supreme Court listen?

Makary Signals Some Interest In US FDA Staff Cuts, Fighting Patent Thickets

 
• By Sarah Karlin-Smith

The FDA Commissioner nominee also commented on trial diversity, the role of public comment and expedited biosimilar reviews during his Senate confirmation hearing.

IGBA Picks Apart Innovator Patent ‘Gaming Systems’

 
• By Urtė Fultinavičiūtė

The International Generic and Biosimilar Medicines Association has introduced its first global intellectual property and competition report, addressing the urgent need to reform current regulations. But, in a bid to increase access to medicines across the world, did it stop short at just IP and patents?

PhRMA Kicks Off Year Attacking China, Wrapping Agenda In American Flag

 
• By Sarah Karlin-Smith

US pharma leadership is painting its mission, particularly its goal to end Medicare price controls, as patriotic and essential to America’s global dominance over China, a move that seems designed to align with President Trump’s priorities.

More from Legal & IP

Kennedy’s Pullback of Public Comment Policy Make May Rules Vulnerable to Lawsuits

 
• By Jill Drachenberg

The Health and Human Services Department's decision to eliminate the Richardson Waiver may be a blow for transparency, but will not completely eliminate scrutiny of regulations, experts said.

Makary US FDA Nomination Advances, Last Minute Hiccup May Offer Clues On Mifepristone

 
• By Sarah Karlin-Smith

President Trump’s CDC director nominee was pulled after vaccine positions appeared too extreme for some Republicans, but the nominations to lead the FDA and NIH advanced to the Senate floor despite last-minute drama.

US FDA May Lose Some Autonomy Under Health Department’s General Counsel Reorg

 
• By Sarah Karlin-Smith

Health and Human Services Secretary Robert F. Kennedy Jr. is moving FDA Chief Counsel Robert Foster to a new senior position as Chief Counsel for Food, Research, and Drugs at HHS. Hilary Perkins will become FDA chief counsel.